A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas
This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.
Inclusion Criteria:
Exclusion Criteria:
Maywood, Illinois 60153, United States
Basking Ridge, New Jersey 07920, United States
Rochester, New York 14642, United States
Dallas, Texas 75246, United States
Seattle, Washington 98109-1023, United States
Ostrava - Poruba, 708 52, Czechia
Homburg/Saar, 66421, Germany
Brzozów, 36-200, Poland
Bucharest, 022328, Romania
Târgu Mureş, 540136, Romania